HOME >> BIOLOGY >> NEWS
Breast cancer and hormone therapy -- A looking-glass mirror?

The medical community has been debating for many years whether, and to what extent, postmenopausal hormone therapy (HT) use is associated with a higher risk of breast cancer, says Professor Amos Pines, President of the International Menopause Society. Although it is agreed that long-term HT slightly increases that risk, the definition of long-term use is still unclear, particularly in view of data showing that it may vary significantly by type of HT (estrogen-alone vs. estrogenprogestin, brand of progestin, dosage). A new study from the Kaiser Permanente health plan[1] raises the question whether trends in breast cancer incidence and use of HT over the past 25 years may be directly linked.

The Womens Health Initiative (WHI) trial was a landmark in menopause medicine since it provided information based on the best available study methodology[2]. By adopting its results as the ultimate source of information, many organizations, medical societies and health authorities actually declared that data derived from observations in the postmenopausal population are less valuable. Nevertheless, during the past few months, several studies have used databases on the incidence of breast cancer, on the one hand, and sales of HT on the other hand, in order to suggest a direct link between trends of hormone use and the number of newly diagnosed breast cancer patients. While such information, by itself, is very important and interesting, conclusions must be drawn with great caution. It is tempting to simplify the observed year-by-year figures on HT use and breast cancer incidence and establish a mirror glass equation: the more postmenopausal hormone use, the more breast cancer, and vice versa. But human biology is far too complicated and the pathophysiology of breast cancer is far too complex to adopt such a mechanistic approach, as the authors of those studies and related Editorials rightly say.

The mere fact that the incidence of lung cancer is higher among
'"/>

Contact: Jean Wright
jwright.ims@btopenworld.com
International Menopause Society
24-Jul-2007


Page: 1 2 3

Related biology news :

1. Breast cancer prognosis runs in the family
2. Breast cancer milieu -- Progression, tamoxifen sensitivity, and DNA reversion
3. Is bigger better? Breast surgery linked to boost in self-esteem and sexuality
4. Breast cancer treatment heats up
5. Genesearch Breast Lymph Node assay detects breast cancer metastases with greater sensitivity
6. Breast Cancer Month story tips from Georgetown University Medical Center
7. Breast density helps predict breast cancer risk
8. Breast stem cells have features similar to basal tumors
9. Breast cancer genetics and more -- press release from PLoS Medicine
10. Breast-sparing surgery an option for women with breast cancer gene mutation, U-M-led study finds
11. Breast implants not associated with cancer risk, study reports

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... Va. (PRWEB) , ... July 08, 2020 , ... ... Latest on Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, ... need a comparability study, but what is the most effective way to complete ...
(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... services, today announced that the company has received ISO9001:2015 certification for the ... and research industries. The decision to pursue ISO9001 accreditation demonstrates Kemp’s commitment ...
Breaking Biology News(10 mins):
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a highly ... closed on the purchase of greenfield for a new, expanded manufacturing facility. The ... 21 acres in the initial acquisition, with an option to purchase an additional ...
(Date:7/31/2020)... Texas (PRWEB) , ... July 29, 2020 , ... ... solutions today announced the launch of its new tagline, “BUILDING FOR LIFE.” The ... biopharmaceutical industry and around the globe, requiring fast track capacity to provide patients ...
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management and ... it did not take off as quickly as people initially expected, and where eSource ... capturing data electronically for clinical trials and then repurposing it for downstream analysis, at ...
(Date:7/18/2020)... ... July 16, 2020 , ... After research model surgery and ... a great surgery is only the beginning of a successful study, while protecting and ... Join Brad Gien, Global Head of Surgery from Envigo in a ...
Breaking Biology Technology:
Cached News: